Cartalax - Cartilax
A short bioregulator peptide (Ala-Glu-Asp) that directly targets cartilage cells, stimulating the body's own collagen synthesis to renew damaged joint cartilage in arthritis and spinal degeneration.
Cartalax is a short regulatory bioactive peptide made of three amino acids (Ala-Glu-Asp), developed through research at the St Petersburg Institute of Bioregulation and Gerontology led by Professor Vladimir Khavinson. It was designed to act as a direct, specific gene regulator for cartilage, joints, the spine and connective tissue. Its extremely small molecular weight lets it cross cell membranes and cartilage cells (chondrocytes) and reach the nucleus. Cartalax binds DNA to stimulate gene expression for the synthesis of type II collagen, proteoglycans and glycosaminoglycans, while inhibiting programmed cell death in cartilage and dampening enzymatic destruction caused by mechanical stress and chronic inflammation.
The genetic key for rebuilding worn cartilage and restoring joint flexibility
If you suffer from joint pain, knee osteoarthritis or stiff vertebrae and are looking for a solution that goes beyond surface painkillers and redirects cartilage cells to rebuild themselves from within, Cartalax is the biological solution for genetically resetting cartilage tissue.
Classification: Cellular bioregulator peptides, joint and cartilage health, connective-tissue renewal (Bioregulators / Cartilage & Joint Regeneration).
Structurally, it is a tiny tripeptide made of alanine, glutamic acid and aspartic acid. This simple arrangement gives it an outstanding ability to cross cellular barriers without breaking down and reach the genetic material inside cartilage cells directly.
Picture the cartilage in a worn joint as a shock-absorbing cushion that has started to dry out and crack, its cells losing the ability to make the protective gel, so that every movement of the bones becomes painful, constant friction.
How it works
Cartalax reaches tired cartilage cells and penetrates their nucleus, binding specific regions of the DNA strand and stimulating the genes responsible for producing collagen and cartilage-cohesion proteins. In parallel, it inhibits the destructive enzymes released by chronic inflammation that wear joints down, and rebalances the metabolism of connective tissue around the ligaments and spine. The result is a gradual restoration of cartilage thickness, better synovial-fluid secretion and less friction pain and morning stiffness, returning natural flexibility to the joint and its ability to bear loads.
In research, Cartalax is studied in models of osteoarthritis, degenerative cartilage disease, rheumatoid arthritis and recovery from acute sports injuries of the knee, shoulder and spine.
Real joint treatment does not end with temporarily numbing pain — it begins by sending a biological code that prompts cartilage cells to repair their own worn cushions.
Reviving cartilage cells and repairing joints from their genetic source. Cartalax is the most notable development in targeted bioregulation research for rescuing cartilage and protecting the spine from wear. It belongs to the class of regulatory bioactive peptides for repairing joints and connective tissue. Its three tiny amino acids penetrate exhausted cartilage cells and reach their nucleus directly, sending direct orders to resynthesise collagen and the flexible matrix around the joint. Its mechanism halts the breakdown of cartilage tissue and dampens the deep inflammation behind joint wear and painful bone-on-bone friction, restoring lost softness and flexibility to joints and vertebrae and their ability to absorb shock. Experts study it as an exceptional solution for knee osteoarthritis and degenerative back pain and for rebuilding musculoskeletal tissue with outstanding efficiency and molecular safety — because comfortable movement begins with biological signals that rebuild your joints' cushions from deep inside the cell.
